AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). For more information, visit www.an2therapeutics.com.
SOURCE AN2 Therapeutics, Inc.

https://www.an2therapeutics.com/

Biotechnology

An2 Therapeutics Closed $80 Million Series B Financing To Advance Novel Nontuberculous Mycobacterial Lung Disease Program

Description

Company Information

Funding Insights

An2 Therapeutics Closed $80 Million Series B Financing To Advance Novel Nontuberculous Mycobacterial Lung Disease Program

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information